[
  {
    "ts": "2026-01-05T03:10:02+00:00",
    "headline": "Is Merck Still Attractive at $106 After Recent Gains and Pipeline Progress?",
    "summary": "Wondering if Merck at around $106 is still a smart buy or if most of the upside is already priced in? This breakdown will help you decide whether the market is being too cautious or not cautious enough. Despite a flat return year to date and a modest 1.6% gain over three years, the stock has climbed 6.7% in the last month and 11.4% over the past year, hinting that sentiment around Merck's long term prospects is quietly improving. Recently, attention has centered on Merck's late stage...",
    "url": "https://finance.yahoo.com/news/merck-still-attractive-106-recent-031002615.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "dc57d881-7aa1-3058-84d7-10a99145a071",
      "content": {
        "id": "dc57d881-7aa1-3058-84d7-10a99145a071",
        "contentType": "STORY",
        "title": "Is Merck Still Attractive at $106 After Recent Gains and Pipeline Progress?",
        "description": "",
        "summary": "Wondering if Merck at around $106 is still a smart buy or if most of the upside is already priced in? This breakdown will help you decide whether the market is being too cautious or not cautious enough. Despite a flat return year to date and a modest 1.6% gain over three years, the stock has climbed 6.7% in the last month and 11.4% over the past year, hinting that sentiment around Merck's long term prospects is quietly improving. Recently, attention has centered on Merck's late stage...",
        "pubDate": "2026-01-05T03:10:02Z",
        "displayTime": "2026-01-05T03:10:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-still-attractive-106-recent-031002615.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-still-attractive-106-recent-031002615.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T06:45:00+00:00",
    "headline": "BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer",
    "summary": "24% ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100) The combination demonstrated a favorable safety and tolerability profile Results ...",
    "url": "https://finance.yahoo.com/news/bioinvent-reports-promising-data-ongoing-064500783.html",
    "source": "ACCESS Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "f8172c38-928f-3fa9-ae1d-ef1a37cbbef5",
      "content": {
        "id": "f8172c38-928f-3fa9-ae1d-ef1a37cbbef5",
        "contentType": "STORY",
        "title": "BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer",
        "description": "",
        "summary": "24% ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100) The combination demonstrated a favorable safety and tolerability profile Results ...",
        "pubDate": "2026-01-05T06:45:00Z",
        "displayTime": "2026-01-05T06:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/accesswire.ca/46e2cb332e043fe93eb50efbeae98e79",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "<![CDATA[24% ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ...]]>",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cZ7nw0Tb4TK4YDcHOJ8wyw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/46e2cb332e043fe93eb50efbeae98e79.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/H7l7hY5scI.Njki1VTGiiQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/46e2cb332e043fe93eb50efbeae98e79.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "ACCESS Newswire",
          "url": "https://www.accessnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bioinvent-reports-promising-data-ongoing-064500783.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bioinvent-reports-promising-data-ongoing-064500783.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BOVNF"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]